Twist Bioscience (TWST) closed at $111.60 on November 13, 2026, down 2.3% from the previous close, on volume of 2,011,671 shares (30-day average 2,766,079).
Data as of November 13, 2026.
13-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 9, 2026 | Call Spread | 20-Nov-26140 : 150 C | 2,216 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the 10 largest for 30, 60 and 90 days
Twist Bioscience Earnings Call Signals Strong Growth Ahead
TipRanks (Sat, 14-Nov 9:42 PM ET)
Leerink Partners Sticks to Its Buy Rating for Twist Bioscience (TWST)
TipRanks (Fri, 13-Nov 9:37 AM ET)
Twist Bio slips despite Q4 beat after underwhelming FY27 outlook
Seeking Alpha News (Thu, 12-Nov 9:26 AM ET)
Twist Bioscience beats top-line and bottom-line estimates; gives Q1 and FY2027 outlook
Seeking Alpha News (Thu, 12-Nov 7:19 AM ET)
Twist Bioscience Announces Fiscal 2026 Fourth Quarter and Full Year Financial Results
Business Wire (Thu, 12-Nov 7:15 AM ET)
Here are the major earnings before the open Thursday
Seeking Alpha News (Wed, 11-Nov 6:00 PM ET)
Twist Bioscience Q4 2026 Earnings Preview
Seeking Alpha News (Wed, 11-Nov 11:53 AM ET)
Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Business Wire (Wed, 11-Nov 8:00 AM ET)
Twist Bioscience to Present at Upcoming Investor Conferences
Business Wire (Mon, 9-Nov 8:00 AM ET)
Why the Next Edge in Antibody Discovery May Be What Labs Remember
Globe Newswire (Wed, 4-Nov 8:15 AM ET)
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.
Twist Bioscience trades on the NASDAQ stock market under the symbol TWST.
As of November 13, 2026, TWST stock price declined to $111.60 with 2,011,671 million shares trading.
TWST has a beta of 1.69, meaning it tends to be more sensitive to market movements. TWST has a correlation of 0.07 to the broad based SPY ETF.
TWST has a market cap of $7.35 billion. This is considered a Mid Cap stock.
Last quarter Twist Bioscience reported $127 million in Revenue and -$.32 earnings per share. This beat revenue expectation by $3 million and missed earnings estimates by -$.07.
In the last 3 years, TWST traded as high as $219.71 and as low as $18.59.
The top ETF exchange traded funds that TWST belongs to (by Net Assets): VTI, VB, ARKE, ARKK, IWM.
TWST has outperformed the market in the last year with a return of +273.2%, while the SPY ETF gained +13.4%. However, in the most recent history, TWST shares have underperformed the stock market with its stock returning -10.9% in the last 3 month period and -27.0% for the last 2 week period, while SPY has returned -2.8% and -0.2%, respectively.
TWST support price is $105.12 and resistance is $123.32 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TWST shares will trade within this expected range on the day.
